FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention claims compounds of formula I or their pharmaceutically acceptable salts, their containing a pharmaceutical composition, methods of treatment and use of said compounds for preparing a drug for treating diseases mediated by complement factor D. In formula I, symbols and groups have values given in claim. Inhibitors described herein act on factor D and inhibit or regulate the complement cascade at the early and significant point of the complement pathway, and reducing ability of factor D to modulate classical and lectin complement pathway.
EFFECT: described herein inhibitors of factor D are able to reduce excessive activation of complement, which is associated with certain autoimmune, inflammatory and neurodegenerative diseases, as well as ischemic-reperfusion injury and cancer.
56 cl, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | 2011 |
|
RU2603637C2 |
| BRIDGED N-CYCLYC SULPHONAMIDO-INHIBITORS OF GAMMA-SECRETASE | 2006 |
|
RU2422443C2 |
| KINASE INHIBITORS | 2012 |
|
RU2623734C9 |
| ARYL, HETEROARYL AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | 2018 |
|
RU2801278C2 |
| NEMATOCIDAL SULPHONAMIDES | 2010 |
|
RU2531317C2 |
| COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | 2019 |
|
RU2795108C2 |
| COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | 2018 |
|
RU2786719C2 |
| NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | 2013 |
|
RU2660429C2 |
| COMPOUNDS FOR TREATING COMPLEMENT-MEDIATED DISORDERS | 2015 |
|
RU2703995C2 |
| 1,1,2,2-TETRA (HETERO) ARYLETHANES OR 1,1,2-TRI (HETERO) ARYL-2-HETEROCYCLYLETHANES AS POTASSIUM CHANNEL INHIBITORS | 2005 |
|
RU2344134C2 |
